Skip to Main Content

Paper Details

Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic.
Oncogene
18
2022
CRBN, H3K4me2, IKZF, IKZF1, IKZF3, IMiDs, Ikaros, Ikaros zinc finger, KMT2A, MLL, MLL-rearranged leukemias, MS40, MS40N1, MS40N2, PROTAC, VHL, WD repeat, WD repeat domain 5, WDR5, anti-, antitumor, cancer, cereblon, chromatin, lysine, patient, primary leukemia, primary leukemia patient cells
Author NameAffiliation
Zhao ZhangMays Cancer Center, University of Texas Health Science Center at San Antonio
Ricky D EdmondsonUniversity of Arkansas for Medical Sciences
Samuel G MackintoshUniversity of Arkansas for Medical Sciences
Jian JinMount Sinai Center for Therapeutics Discovery, Icahn School of Medicine at Mount Sinai
Jian JinDepartments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
  • 1 - 5

Datasets

Release 1.2